OncoCyte (OCX) Competitors $3.18 +0.45 (+16.30%) Closing price 06/17/2025Extended Trading$3.18 0.00 (0.00%) As of 06/17/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCX vs. HUMA, RZLT, UPXI, TERN, ARCT, CMPX, ATXS, SNDL, GOSS, and MBXShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Humacyte (HUMA), Rezolute (RZLT), Upexi (UPXI), Terns Pharmaceuticals (TERN), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), Astria Therapeutics (ATXS), SNDL (SNDL), Gossamer Bio (GOSS), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Its Competitors Humacyte Rezolute Upexi Terns Pharmaceuticals Arcturus Therapeutics Compass Therapeutics Astria Therapeutics SNDL Gossamer Bio MBX Biosciences Humacyte (NASDAQ:HUMA) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends. Do analysts rate HUMA or OCX? Humacyte presently has a consensus price target of $11.71, suggesting a potential upside of 417.19%. OncoCyte has a consensus price target of $6.06, suggesting a potential upside of 90.94%. Given Humacyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe Humacyte is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00OncoCyte 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do institutionals and insiders believe in HUMA or OCX? 44.7% of Humacyte shares are held by institutional investors. Comparatively, 55.3% of OncoCyte shares are held by institutional investors. 5.1% of Humacyte shares are held by company insiders. Comparatively, 2.1% of OncoCyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation and earnings, HUMA or OCX? OncoCyte has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than OncoCyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$1.57M223.79-$148.70M-$0.69-3.28OncoCyte$3.84M23.63-$60.66M-$3.53-0.90 Is HUMA or OCX more profitable? Humacyte has a net margin of 0.00% compared to OncoCyte's net margin of -1,516.06%. Humacyte's return on equity of 0.00% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A -73.59% OncoCyte -1,516.06%-215.59%-27.23% Does the media favor HUMA or OCX? In the previous week, Humacyte had 2 more articles in the media than OncoCyte. MarketBeat recorded 2 mentions for Humacyte and 0 mentions for OncoCyte. Humacyte's average media sentiment score of 0.00 equaled OncoCyte'saverage media sentiment score. Company Overall Sentiment Humacyte Neutral OncoCyte Neutral Which has more volatility and risk, HUMA or OCX? Humacyte has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. SummaryHumacyte beats OncoCyte on 11 of the 16 factors compared between the two stocks. Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.80M$7.29B$5.54B$8.95BDividend YieldN/A2.78%5.38%4.08%P/E Ratio-0.9027.9427.3820.03Price / Sales23.6332.39422.31120.16Price / CashN/A22.0836.6357.47Price / Book-4.546.698.085.67Net Income-$60.66M$233.06M$3.16B$248.47M7 Day PerformanceN/A2.20%2.12%2.90%1 Month Performance3.42%4.93%4.43%5.75%1 Year Performance3.76%35.84%35.62%21.36% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte2.0312 of 5 stars$3.18+16.3%$6.06+90.9%+7.3%$90.80M$3.84M-0.90120HUMAHumacyte2.3542 of 5 stars$2.21-4.3%$11.71+430.1%-54.8%$358.32M$1.57M-3.20150Gap DownRZLTRezolute3.01 of 5 stars$4.03-1.9%$11.83+193.6%+15.4%$351.48MN/A-3.5040Positive NewsUPXIUpexi3.4693 of 5 stars$10.00+8.1%$16.00+60.0%-68.0%$350.72M$26M0.00130Upcoming EarningsGap UpTERNTerns Pharmaceuticals4.0744 of 5 stars$3.68-5.6%$15.63+324.6%-36.6%$340.61MN/A-3.3840ARCTArcturus Therapeutics3.7723 of 5 stars$12.51+1.8%$53.50+327.7%-36.6%$333.31M$152.31M-4.94180News CoverageAnalyst ForecastCMPXCompass Therapeutics3.213 of 5 stars$2.54+5.8%$13.13+416.7%+197.7%$331.88M$850K-6.2020News CoverageAnalyst UpgradeATXSAstria Therapeutics1.4564 of 5 stars$5.61-4.3%$30.00+434.8%-36.1%$330.70MN/A-3.0030News CoverageSNDLSNDL3.3156 of 5 stars$1.24-0.8%$3.63+192.3%-33.5%$328.47M$671.81M-4.282,516Positive NewsGOSSGossamer Bio3.6402 of 5 stars$1.37-4.9%$7.75+465.7%+26.1%$327.32M$114.70M-5.96180MBXMBX Biosciences2.4106 of 5 stars$9.73-0.1%$37.50+285.4%N/A$325.22MN/A0.0036 Related Companies and Tools Related Companies Humacyte Alternatives Rezolute Alternatives Upexi Alternatives Terns Pharmaceuticals Alternatives Arcturus Therapeutics Alternatives Compass Therapeutics Alternatives Astria Therapeutics Alternatives SNDL Alternatives Gossamer Bio Alternatives MBX Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
